首页> 外文期刊>Antiviral chemistry & chemotherapy >New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus.
【24h】

New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus.

机译:抗SARS冠状病毒的新抗病毒药,疫苗和经典公共卫生干预措施。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R0 value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.
机译:严重急性呼吸道综合症(SARS)是由最近发现的两种冠状病毒之一引起的。该病毒是从东南亚(SE)亚洲哺乳动物中产生的:麝猫,相关物种或大鼠物种。该病毒的潜伏期长,繁殖数(R0值)低,因此2004年的首次爆发是由卫生和检疫控制的。但是,医疗体系受到损害,经济成本非常高。幸运的是,该病毒很容易在Vero E6细胞中培养,因此,使用经典的细胞培养和电子显微镜技术,在发现病毒后的几周内就开始寻找新的抗病毒药和疫苗。分子诊断有助于快速准确地诊断,这是控制疫情爆发的关键因素。广谱分子利巴韦林与皮质类固醇一起在东南亚用于感染患者。回想起来,许多患者由于精心护理而得以幸存。目前唯一接受的干预措施是干扰素。冠状病毒复制子系统应有助于快速筛选新的抑制剂,复杂的病毒复制机制将确保针对至少五个分子靶标(尤其是病毒蛋白酶)开发药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号